Taurohyocholic Acid-d4 (sodium salt)
(Synonyms: Taurine Hyocholate-d4, Tauro-γ-muricholic Acid-d4, Taurohyocholate-d4, THCA-d4) 目录号 : GC49010
An internal standard for the quantification of taurohyocholic acid
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Taurohyocholic acid-d4 (THCA-d4) is intended for use as an internal standard for the quantification of THCA by GC- or LC-MS. THCA is a taurine-conjugated form of the porcine-specific primary bile acid hyocholic acid .1 THCA inhibits precipitation of cholesterol crystals by stabilizing cholesterol in the liquid-crystalline phase.2 It prevents cholestasis and cellular necrosis induced by taurolithocholic acid in isolated rat liver.3 THCA levels are increased in the urine of patients with hepatitis B-induced cirrhosis.4
1.WahlstrÖm, A., Sayin, S.I., Marschall, H.-I., et al.Intestinal crosstalk between bile acids and microbiota and its impact on host metabolismCell Metab.24(1)41-50(2016) 2.Juste, C., Catala, I., Henry, R., et al.Influence of bile salt molecular species on cholesterol crystallization from supersaturated model bilesBiochim. Biophys. Acta.1254(1)89-97(1995) 3.Scholmerich, J., Kitamura, S., Baumgartner, U., et al.Taurohyocholate, taurocholate, and tauroursodeoxycholate but not tauroursocholate and taurodehydrocholate counteract effects of taurolithocholate in rat liverRes. Exp. Med. (Berl.)190(2)121-129(1990) 4.Wang, X., Xie, G., Zhao, A., et al.Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosisJ. Proteome Res.15(4)1126-1134(2016)
| Cas No. | N/A | SDF | |
| 别名 | Taurine Hyocholate-d4, Tauro-γ-muricholic Acid-d4, Taurohyocholate-d4, THCA-d4 | ||
| Canonical SMILES | O[C@@H]1C([2H])([2H])C[C@@]2(C)[C@@]([C@@H](O)[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCCS([O-])(=O)=O)=O)([H])C1([2H])[2H].[Na+] | ||
| 分子式 | C26H40D4NO7S·Na | 分子量 | 541.7 |
| 溶解度 | DMF: 30 mg/ml,DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.846 mL | 9.2302 mL | 18.4604 mL |
| 5 mM | 0.3692 mL | 1.846 mL | 3.6921 mL |
| 10 mM | 0.1846 mL | 0.923 mL | 1.846 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。